FDA approves Orca Bio’s cell therapy to improve transplant outcomes

Nate Fernhoff, Orca Bio CEO July 1, 2026 11:44 AM EDT PharmaCell/Gene TxFDA+ FDA ap­proves Or­ca Bio’s cell ther­a­py to im­prove trans­plant out­comes Lei Lei Wu News Reporter The FDA gave the go-ahead to Or­ca Bio’s T cell ther­a­py that would re­duce trans­plant-re­lat­ed com­pli­ca­tions for blood can­cer pa­tients. The ther­a­py will be brand­ed … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER